The short version
4 companies supply this market — a reasonable cushion if one runs into trouble.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Cyclophosphamide · CYCLOPHOSPHAMIDE 500 mg/2.5mL · Injection · Intravenous · Eugia US LLC
NDC 55150-0270-99 · 1 VIAL, MULTI-DOSE in 1 CARTON / 2.5 mL in 1 VIAL, MULTI-DOSE · NDA · View full market →
4 companies supply this market — a reasonable cushion if one runs into trouble.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.
Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Manufacturer list price as filed — not what pharmacies actually pay after discounts.
Not scored — fragility is computed for NADAC-priced NDCs.
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
There's no legal definition — it meets 1 of 6 public criteria. Why that matters →
| Type | Number / code | Expires |
|---|---|---|
| patent | 9662342 | Jun 26, 2035 |
| patent | 9662342 | Jun 26, 2035 |
| patent | 9662342 | Jun 26, 2035 |
No FDA shortage reports for this drug or its presentations.
No enforcement reports list this package NDC.
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Avyxa Pharma, LLC | CYCLOPHOSPHAMIDE 500 mg/mL | Jul 15, 2026 | Sep 3, 2026 |
| Avyxa Pharma, LLC | CYCLOPHOSPHAMIDE 1 g/2mL | Jul 15, 2026 | Sep 3, 2026 |
| Piramal Pharma Solutions Inc. | CYCLOPHOSPHAMIDE ANHYDROUS 200 mg/mL | Jul 15, 2026 | Sep 3, 2026 |
| Eugia US LLC | CYCLOPHOSPHAMIDE 500 mg/2.5mL | Jul 15, 2026 | Sep 2, 2026 |
| Eugia US LLC | CYCLOPHOSPHAMIDE 2 g/10mL | Jul 15, 2026 | Sep 2, 2026 |
| Eugia US LLC | CYCLOPHOSPHAMIDE 1 g/5mL | Jul 15, 2026 | Sep 2, 2026 |
| Nexus Pharmaceuticals, LLC | CYCLOPHOSPHAMIDE 200 mg/mL | Jul 15, 2026 | Aug 31, 2026 |
| Avyxa Pharma, LLC | CYCLOPHOSPHAMIDE 2 g/4mL | Jul 15, 2026 | Aug 28, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
DrugDashboards, "Cyclophosphamide — NDC 55150-0270-99," retrieved September 3, 2026, https://drugdashboards.com/drug/55150027099.
Free to cite with attribution — see how the data is put together.